Bone-Saving drug may shield patients after bariatric surgery
NCT ID NCT04742010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single infusion of zoledronic acid can prevent bone and muscle loss in adults aged 35 and older who are undergoing bariatric surgery. Fifty-nine participants were randomly assigned to receive either the drug or a placebo. The main goal was to measure changes in spine bone density using a special CT scan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital South West Jutland
Esbjerg, 6700, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?